Drugs / AN01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07554365 | May → Jun 2026 overdue | — | AirNexis Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AN01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07554365 ↗ |
| Action | Inhibit | “dual inhibitor of phosphodiesterase 3 and 4 (PDE3/4)” NCT07554365 ↗ |
| Modality | Small molecule | “selective small-molecule” NCT07554365 ↗ |
| Route | Inhaled | “AN01 Inhalation Powder” NCT07554365 ↗ |